Consequently, the discovery of the endogenous inverse agonist LEAP2 may reveal a potential therapeutic target for ghrelin-related diseases, including type 2 diabetes and obesity, due to its reciprocal relationship with ghrelin4 and elevated expression levels following RYGB.7 This evidence concerns the gene GHRL and obesity disorder.